Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
B. Masson (Le Plessis-Robinson, France), H. Le Ribeuz (Le Plessis-Robinson, France), J. Sabourin (Châtenay-Malabry, France), E. Woodhouse (Leeds, United Kingdom), R. Foster (Leeds, United Kingdom), Y. Ruchon (Le Plessis-Robinson, France), M. Dutheil (Le Plessis-Robinson, France), A. Boët (Le Plessis-Robinson, France), M. Ghigna (Le Plessis-Robinson, France), O. Mercier (Le Plessis-Robinson, France), D. Beech (Leeds, United Kingdom), J. Benitah (Châtenay-Malabry, France), M. Bailey (Leeds, United Kingdom), M. Humbert (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), V. Capuano (Le Plessis-Robinson, France), F. Antigny (Le Plessis-Robinson, France). Late Breaking Abstract - Involvement of Orai1 Ca2+ channel in the pathogenesis of pulmonary arterial hypertension. Orai1 as a new potential therapeutic target ?. 599

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Contribution of STIM-activated TRPC-ORAI channels to the intermittent hypoxia-induced pulmonary hypertension Source: Virtual Congress 2020 – Cellular stress in respiratory diseases Year: 2020 Late Breaking Abstract - Implication of the KATP Sur2b/Kir6.1 in the physiopathology of pulmonary arterial hypertension Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Late Breaking Abstract - NGF induces pulmonary arterial hyperreactivity through increased connexin-43 expression: potential role in pulmonary hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Classical transient receptor potential channel 6 (TRPC6) is a key regulator of acute hypoxic pulmonary vasoconstriction Source: Eur Respir J 2007; 30: Suppl. 51, 55s Year: 2007 SUR1/Kir6.2 potassium channel a new actor involved in pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 The effects of angiotensin II and related peptides on intracellular Ca2+ release in human lung fibroblasts Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Late Breaking Abstract - CRAC channel inhibition by RP3128 triggers potent anti-inflammatory effects in COPD or asthmatic patient-derived primary cells Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract: Denufosol: A novel ion channel regulator and investigational early-intervention therapy for cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010 Loss of response to calcium channel blockers after long-term follow up in idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Caveolin-1 regulation of store-operated Ca2+ influx in human airway smooth muscle Source: Eur Respir J 2012; 40: 470-478 Year: 2012 The emerging role of transient receptor potential channels in chronic lung disease Source: Eur Respir J, 50 (2) 1601357; 10.1183/13993003.01357-2016 Year: 2017 The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade Source: Eur Respir J, 50 (6) 1701141; 10.1183/13993003.01141-2017 Year: 2017 Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? Source: Eur Respir J 2010; 35: 730-734 Year: 2010 Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020 Year: 2021 Activation of TRPV4 causes bronchoconstriction: A possible role in respiratory disease? Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Late Breaking Abstract -  Blockade of ß2-adrenoceptor augments anaphylaxis-induced increase in pulmonary vascular permeability in anesthetized mice Source: International Congress 2017 – Animal models of asthma and allergies Year: 2017 Effects of urocortin-2 on cellular Ca2+ homeostasis in right heart failure induced by pulmonary artery hypertension Source: International Congress 2018 – On the right path: understanding and improving the function of an overloaded right heart ventricle Year: 2018 Late Breaking Abstract - Assessment of a ciliary transport protein in airway cells reveals novel pattern in cystic fibrosis Source: International Congress 2017 – Cystic fibrosis: clinical issues Year: 2017